Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

Susan F. Slovin, MD, PhD
Published: Wednesday, Aug 16, 2017



Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
 
SELECTED
LANGUAGE


Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x